This is a routine promotional article with no new clinical data or regulatory milestones. Monitor for any actual government funding announcements or FDA interactions, but the filing itself provides no trading catalyst.
Price Chart
Executive Summary
AIM ImmunoTech filed an 8-K furnishing a sponsored article by CEO Thomas Equels in Breaking Defense, promoting Ampligen (rintatolimod) as a potential broad-spectrum prophylactic antiviral for Ebola and COVID-19. The article cites preclinical mouse-model data showing 100% survival in one treated cohort vs. 100% mortality in controls, but Ampligen is not FDA-approved for any biodefense indication. This is a routine Regulation FD disclosure with no new financial data, clinical results, or material corporate developments.
Key Facts
- CEO Thomas Equels authored a sponsored article in Breaking Defense on August 11, 2026, discussing Ampligen's potential as a broad-spectrum prophylactic antiviral.
- Preclinical mouse-model data from USAMRIID showed 100% survival in one rintatolimod-treated cohort vs. 100% mortality in controls for Ebola.
- Ampligen is not FDA-approved for Ebola virus disease, Bundibugyo virus disease, coronaviruses, or any biodefense indication.
- The filing contains no financial data, guidance, or material corporate events.
Financial Impact
No financial impact disclosed in the filing.
Risk Factors
- Ampligen has no FDA approval for any biodefense indication; preclinical results may not replicate in humans.
- The company has limited financial resources and depends on government funding for further development.
- Forward-looking statements about broad-spectrum antiviral potential are speculative and not evidence of clinical efficacy.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001493152-26-036996 |
| Exhibit: ex99-1.htm | 0001493152-26-036996 |
| Document: 0001493152-26-036996-index-headers.html | 0001493152-26-036996 |
| Document: 0001493152-26-036996-index.html | 0001493152-26-036996 |
| Document: 0001493152-26-036996.txt | 0001493152-26-036996 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 30, 2026 25d ago | DEF 14A | $0.1877 | awaiting T+20 | — | $0.1600 (−14.76%) |
Sep 22, 2026 4w ago | Press Release | $0.2156 $0.1662 | ▼ −22.91% | ▼ −22.35% | $0.1600 (−25.79%) |
Sep 14, 2026 5w ago | 8-K | $0.2100 | awaiting T+20 | — | $0.1600 (+23.81%) |
Aug 11, 2026 10w ago | 8-K | $0.2500 $0.2332 | ▼ −6.72% | ▼ −5.66% | $0.1600 (−36.00%) |
Aug 10, 2026 10w ago | 8-K | $0.2630 | awaiting T+20 | — | $0.1600 (+39.16%) |
Aug 10, 2026 10w ago | Press Release | $0.2630 | awaiting T+20 | — | $0.1600 (+39.16%) |
Aug 5, 2026 11w ago | 8-K | $0.2800 $0.2346 | ▼ −16.21% | ▼ −15.61% | $0.1600 (−42.86%) |
Aug 3, 2026 11w ago | Press Release | $0.2600 $0.2260 | ▼ −13.08% | ▼ −14.31% | $0.1600 (−38.46%) |
Jun 24, 2026 17w ago | EFFECT | $0.3740 $0.2534 | ▲ +32.25% | ▲ +34.18% | $0.1600 (+57.22%) |
Jun 18, 2026 18w ago | S-1 | $0.3799 $0.2730 | ▲ +28.14% | ▲ +28.67% | $0.1600 (+57.88%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers